Cardiology · Medical Literature
Extended Dual Antiplatelet Therapy for Multivessel Coronary Artery Disease.
Abstract
Patients with multivessel coronary artery disease often receive 12 months of dual antiplatelet therapy (DAPT) after stenting to reduce the risk of ischemic events. Whether extending DAPT beyond 12 months in event-free patients with multivessel disease provides a benefit is uncertain. We conducted an open-label, randomized trial at 97 centers in China. Patients 18 to 75 years of age with multivessel coronary artery disease who had no major ischemic or bleeding events while receiving DAPT for 12 months after implantation of a drug-eluting stent were randomly assigned in a 1:1 ratio to receive an additional 12 months of DAPT (clopidogrel plus aspirin) or aspirin monotherapy. The primary efficacy end point was a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. The primary safety end point was clinically relevant or major bleeding (i.e., a bleeding event of Bleeding Academic Research Consortium [BARC] type ≥2; BARC types range from 0 to 5, with higher values indicating greater severity of bleeding). A total of 8250 patients were randomly assigned to receive extended DAPT (4125 patients) or aspirin monotherapy (4125 patients). The median follow-up was 34.3 months. A primary efficacy end-point event occurred in 222 patients in the DAPT group and in 266 patients in the aspirin-monotherapy group (36-month Kaplan-Meier cumulative incidence, 5.8% vs. 6.8%; hazard ratio, 0.82; 95% confidence interval [CI], 0.69 to 0.98; P = 0.03). Clinically relevant or major bleeding occurred in 51 patients in the DAPT group and in 57 patients in the aspirin-monotherapy group (36-month Kaplan-Meier cumulative incidence, 1.4% vs. 1.5%; hazard ratio, 0.89; 95% CI, 0.61 to 1.30; P = 0.54). Among patients with multivessel coronary artery disease who were in stable condition 12 months after implantation of a drug-eluting stent, extending DAPT with clopidogrel and aspirin for an additional 12 months led to a lower risk of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke than continuing aspirin alone, without an increased risk of bleeding. (Funded by the National Natural Science Foundation of China and others; DAPT-MVD ClinicalTrials.gov number, NCT04624854.).
Clinical relevance
In patients with multivessel coronary artery disease who are event-free after 12 months of DAPT following drug-eluting stent implantation, does extending DAPT (clopidogrel plus aspirin) for an additional 12 months reduce major cardiovascular events compared with aspirin monotherapy, without increasing clinically significant bleeding? __SNAPSHOT__ {"studyDesign":"Open-label, multicenter, randomized controlled trial (DAPT-MVD; NCT04624854)","setting":"97 centers in China","sampleSize":"n=8,250 (extended DAPT: n=4,125; aspirin monotherapy: n=4,125)","population":"Adults aged 18–75 years with multivessel coronary artery disease who had no major ischemic or bleeding events during the first 12 months of DAPT following drug-eluting stent implantation. Mean age approximately 61 years; approximately one-third were women; mean BMI approximately 25 kg/m².","intervention":"Extended DAPT: clopidogrel plus aspirin for an additional 12 months (months 12–24 post-stent)","comparator":"Aspirin monotherapy for 12 months (months 12–24 post-stent)","primaryOutcome":"Efficacy: composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke. Safety: clinically relevant or major bleeding (BARC type ≥2)","followUp":"Median follow-up of 34.3 months (Kaplan–Meier estimates reported at 36 months)","fundingSource":"Government/non-profit: National Natural Science Foundation of China, Tou-Yan Innovation Team Program of Heilongjiang Province, Chinese Society of Cardiology Clinical Research Special Fund; partial industry support from Lepu Medical Technology"}
Key findings
Primary Efficacy Endpoint: The composite of cardiovascular death, nonfatal MI, or nonfatal stroke occurred in 222 patients (36-month Kaplan–Meier cumulative incidence 5.8%) in the extended DAPT group vs. 266 patients (6.8%) in the aspirin monotherapy group (HR 0.82; 95% CI 0.69–0.98; p=0.03). Absolute risk reduction: 1.0 percentage point (calculated). Relative risk reduction: approximately 18% (calculated). NNT over the treatment/follow-up period: approximately 100 patients to prevent one primary composite event (calculated). The efficacy benefit was driven largely by a reduction in nonfatal MI (reported as approximately 32% lower relative risk with extended DAPT); cardiovascular death and all-cause death were nearly identical between groups. The ischemic benefit appeared to emerge after approximately 6 months of extended therapy, and the majority of MI events occurred in non-target coronary segments, suggesting protection against de-novo atherothrombotic events rather than stent-related events. Primary Safety Endpoint: BARC ≥2 bleeding occurred in 51 patients (1.4%) in the extended DAPT group vs. 57 patients (1.5%) in the aspirin monotherapy group (HR 0.89; 95% CI 0.61–1.30; p=0.54), indicating no statistically significant increase in clinically relevant or major bleeding with extended DAPT.
Practice implications
This trial establishes that, in a carefully selected population — multivessel CAD patients who are younger (mean age ~61 years), lean (mean BMI ~25), and who have already tolerated 12 months of DAPT without ischemic or hemorrhagic events — extending clopidogrel plus aspirin for a second year reduces major cardiovascular events with a statistically significant but modest absolute benefit (~1% ARR) and without a measurable bleeding penalty. The finding that most MI events arose in non-target segments underscores that the protection is likely systemic atherothrombotic rather than stent-specific. Several important boundaries of generalizability must be acknowledged: (1) The trial enrolled exclusively in China, and clopidogrel pharmacogenomics (CYP2C19 polymorphisms) differ across ethnic populations, potentially affecting both efficacy and safety when extrapolated to non-Asian patients. (2) Patients with high obesity prevalence—common in Western populations—were not well represented. (3) Patients who experienced early ischemic or bleeding events during the initial 12 months were excluded, creating a survivor-selected cohort at particularly low hemorrhagic risk. (4) The trial used clopidogrel, not the more potent P2Y12 inhibitors (ticagrelor, prasugrel) currently preferred in ACS practice internationally, limiting direct comparability to contemporary post-ACS regimens. (5) The open-label design introduces the possibility of ascertainment bias for soft endpoints, though outcome adjudication was blinded. (6) The absolute risk reduction is small (1%), and the 95% CI for the HR just barely excludes 1.0, warranting cautious interpretation. The trial does not establish a mortality benefit and does not apply to elderly patients, those with high bleeding risk, or those with single-vessel disease. Practice change is plausible in the specific phenotype studied but should be individualized; confirmation in diverse, non-Asian populations and with more potent P2Y12 agents would be desirable before broad adoption. Only the abstract was available for this summary; full data tables, subgroup analyses, and protocol details could not be reviewed. __LIMITATIONS__ Open-label design: patients and treating physicians were aware of assignment, creating potential for behavior modification and differential ascertainment of soft outcomes; outcome adjudication was blinded,Exclusive enrollment in China limits generalizability to non-Asian populations, particularly given ethnic variation in CYP2C19 metabolizer status affecting clopidogrel efficacy,Survivor selection bias: exclusion of patients with any major ischemic or bleeding event in the first 12 months creates an enriched low-bleeding-risk cohort that may not reflect real-world multivessel CAD populations,Use of clopidogrel rather than more potent P2Y12 inhibitors (ticagrelor, prasugrel); results cannot be directly extrapolated to regimens favored in ACS practice in North America or Europe,The trial population was relatively young (mean ~61 years) and lean (mean BMI ~25), limiting applicability to older and higher-BMI patients who carry greater bleeding risk,Modest absolute risk reduction (1.0 percentage point, calculated) with a borderline statistically significant HR (lower boundary of 95% CI 0.69, upper boundary 0.98); precision is limited,No all-cause or cardiovascular mortality benefit demonstrated; long-term mortality implications of extended therapy remain unclear,Partial industry funding (Lepu Medical Technology) introduces potential conflicts of interest,Median follow-up of 34.3 months extends beyond the 12-month intervention period, but long-term durability of benefit after DAPT cessation is not established,Only the abstract was available for this structured review; full methodological details, pre-specified secondary endpoints, subgroup analyses, and statistical analysis plan could not be assessed __BOTTOM_LINE_CATEGORY__ potentially_practice_informing __BOTTOM_LINE__ In event-free patients with multivessel CAD after drug-eluting stent implantation, extending clopidogrel-based DAPT for a second year beyond the standard 12 months produced a statistically significant but small absolute reduction in cardiovascular death, MI, or stroke (~1% ARR; HR 0.82) without increasing BARC ≥2 bleeding. These findings apply most directly to younger, lower-bleeding-risk, East Asian patients and should be interpreted cautiously before extending to older, higher-bleeding-risk, or non-Asian populations. Patient-specific ischemic-bleeding risk assessment—including DAPT score—should guide individualized decisions pending confirmatory trials in more diverse cohorts.